Monitor the final prospectus for the actual offering size, price, and net proceeds. The stock is trading near $1.71 with massive existing warrant overhang (37M shares from prior offerings) and an active ATM facility — any pricing near or below market will add further dilution pressure. Watch for the closing date and subsequent trading volume to gauge absorption.
Price Chart
Executive Summary
Biomea Fusion is conducting a dilutive underwritten public offering of common stock and pre-funded warrants at an undisclosed price, with the stock trading at $1.71 as of September 21, 2026. The offering is part of a $300M shelf registration and is expected to fund Phase II development of icovamenib in diabetes and clinical development of BMF-650 in obesity. The number of shares and proceeds are not yet finalized, but the filing warns of immediate and substantial dilution to new investors.
Key Facts
- Biomea Fusion is offering an undisclosed number of common shares and pre-funded warrants via a 424B5 preliminary prospectus supplement.
- Stock closed at $1.71 on September 21, 2026, prior to the filing.
- The offering is part of a $300.0 million shelf registration (File No. 333-289262).
- Net tangible book value as of June 30, 2026 was $12.1 million, or $0.17 per share, based on 72,483,852 shares outstanding.
- The company has 37,024,389 shares issuable upon exercise of warrants from prior June 2025 and October 2025 offerings, plus up to $100M in shares available under an ATM agreement with Piper Sandler.
- Proceeds will fund Phase II development of icovamenib in type 1/type 2 diabetes, registrational studies, and clinical development of BMF-650 (oral GLP-1 RA) in obesity.
- Underwriter is Konik Capital Partners (T.R. Winston & Co.); underwriter warrants equal 7% of shares sold at 250% of offering price.
- Lock-up agreements in place for 60 days for the company and its directors/executive officers.
- The filing is preliminary — share count, offering price, and net proceeds are all placeholders (undisclosed).
Financial Impact
Undisclosed offering size; net tangible book value was $12.1M ($0.17/share) as of June 30, 2026; the company warns of immediate and substantial dilution to new investors.
Risk Factors
- Immediate and substantial dilution to new investors — offering price will exceed net tangible book value per share.
- Massive existing overhang: 37M shares from June/October 2025 warrants plus up to $100M ATM facility.
- Clinical-stage biotech with no approved products; pipeline risk for icovamenib and BMF-650.
- Preliminary filing — final terms unknown; potential for aggressive pricing if demand is weak.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-397909 |
| Document: 0001193125-26-397909-index-headers.html | 0001193125-26-397909 |
| Document: 0001193125-26-397909-index.html | 0001193125-26-397909 |
| Document: 0001193125-26-397909.txt | 0001193125-26-397909 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6424 (−22.97%) |
Oct 13, 2026 14d ago | Press Release | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6424 (−22.97%) |
Sep 23, 2026 4w ago | Press Release | $1.44 $1.33 | ▼ −7.64% | ▼ −6.96% | $0.6424 (−55.39%) |
Sep 22, 2026 5w ago | 424B5 | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6424 (+55.39%) |
Sep 22, 2026 5w ago | Press Release | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6424 (+55.39%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.17 $1.18 | ▲ +0.85% | ▲ +0.18% | $0.6424 (−45.09%) |
Jun 5, 2026 20w ago | Press Release | $1.15 $1.20 | ▲ +4.35% | ▲ +2.24% | $0.6424 (−44.14%) |
May 11, 2026 24w ago | 8-K | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6424 (−59.34%) |
May 11, 2026 24w ago | Press Release | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6424 (−59.34%) |
Apr 28, 2026 26w ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $0.6424 (−58.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers